About Us

Founded in April 2003, Cathay Venture Inc. (“Cathay Venture”) is a member of Cathay Financial Holding Co., Ltd. (Cathay FHC). We are a venture capital investment firm that focuses on investing in unlisted companies with growth potential and works with its portfolio companies to help them realize their highest potential and value.

Cathay FHC (TSE:2882) is the largest financial holding company in Taiwan by asset size. As a full-service institution, its portfolio spans insurance, banking, securities, and asset management. Leveraging an extensive network of branches and professional sales teams across Taiwan and Southeast Asia (SEA), Cathay FHC has established a robust platform that offers customers a seamless, one-stop shop for all their financial needs.

Cathay Venture is an evergreen venture capital fund distinguished by its investment flexibility, enabling us to support high-quality companies across all stages—from seed to pre-IPO. Since our establishment, we have invested in more than 400 companies. Leveraging extensive experience in unlisted company investments and hands-on collaboration, we add value to our portfolio firms through a collaborative approach, providing strategic assistance in management, operations, and corporate governance.


Investment Focus

    Cathay Venture focuses on key industries with long-term growth potential. Our primary investment directions include:

    1. Frontier Technology
    2. Biotechnology and Healthcare
    3. FinTech
    4. High-quality Overseas Deal Sourcing

    1.Frontier Technology:
    • With the rising demand for artificial intelligence (AI) infrastructure, Cathay Venture actively invests in sectors driven by architectural evolution and advancements in manufacturing technologies. These include hardware equipment and peripherals, the semiconductor supply chain, key components, smart wearable devices, and robotics.
    • The application layer of AI is expected to become the core of future value creation. Cathay Venture prioritizes investments in application software and vertical solutions that can significantly reduce enterprise costs and enhance operational efficiency.

    2.Biotechnology and Healthcare:
    • Cathay Venture focuses on innovative biopharmaceuticals, with a particular emphasis on next-generation antibody therapies such as antibody-drug conjugates (ADCs) and multispecific antibodies. We also strategically invest in the development of orphan drugs and 505(b)(2) pharmaceuticals with significant growth potential.
    • We actively monitor global trends in smart healthcare startups, prioritizing AI-assisted diagnostics and AI-driven therapeutic solutions to capture high-potential opportunities for investment and development.

    3.FinTech:
    • With the maturation of agentic AI, blockchain, and next-generation financial infrastructure, financial services are evolving toward autonomous transactions, product innovation, and enhanced operational efficiency. Cathay Venture is proactively positioning itself to seize investment opportunities in these emerging domains, including AI agent applications, financial infrastructure, blockchain, and stablecoins.

    4.High-quality Overseas Deal Sourcing:
    • With a strategic focus on strengthening global supply chain resilience and advancing technological competitiveness, Cathay Venture prioritizes investments in the overseas manufacturing and R&D facilities of Taiwanese enterprises, as well as in critical components and materials. While we continue to expand our footprint in frontier technology sectors across the U.S., Europe, and Japan, we are actively strengthening our presence in SEA to capture growth from regional supply chain shifts and rising domestic demand. This diversified approach effectively mitigates regional risks, optimizes portfolio allocation, and generates sustainable long-term returns.

Contact Us

Tel: 886-2-77119889
Fax: 886-2-77113988
Add: Room B2, 7F., No.68, Sec. 5, Zhongxiao E. Rd., Xinyi Dist., Taipei City 11065, Taiwan, R.O.C.
Email: 80357826@cathaycapital.com.tw